Pharvaris N.V.
NASDAQ:PHVSBiotechnology
-$0.64 today
- Market cap
- $2.21B
- Beta
- -2.33
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.59
Volume 0.39M
Average 0.31M
PHVS Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Pharvaris N.V.NASDAQ: PHVS
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses grows, but more slowly than its trailing trend
Q3 FY2026 operating expenses of €50.08M rose 26.3% year over year, behind the +125.2% change in trailing-twelve-month operating expenses. Sequentially, it fell 1.4% from the prior quarter. Over 3 fiscal years it compounded at +25.1% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +26.3% toward the trailing-twelve-month pace of +125.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
EUR · from the income statement
- Latest · FY2025
- 169.82M EUR
- Year-over-year change
- +16.6%
- 4-year CAGR
- +33.1%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 169.82M | +16.6% |
| FY2024 | 2024-12-31 | 145.69M | +50.3% |
| FY2023 | 2023-12-31 | 96.91M | +11.8% |
| FY2022 | 2022-12-31 | 86.71M | +60.2% |
| FY2021 | 2021-12-31 | 54.14M | — |
Operating Expenses vs competitors
How PHVS compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +125.2% is the 2nd highest of 7, against a peer median of +27.8%.
- Over three fiscal years its annual growth of +25.1% compares with a peer median of +9.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $902.93B USD | +47406.7% | +10.9% | 87.9% | |
| LTM Sep 2026 | $753.04M USD | +45.8% | +8.5% | 115.7% | |
| LTM Jun 2026 | $534.75M USD | +9.9% | +7.6% | 56.9% | |
| LTM Jun 2026 | $415.76M USD | +76.1% | +50.9% | — | |
| LTM Mar 2026 | $299.02M USD | +4.7% | +22.2% | 81.0% | |
| LTM Sep 2026 | €193.36M EUR | +125.2% | +25.1% | — | |
| LTM Mar 2026 | $28.98M USD | -43.4% | -24.8% | 3377.9% | |
| Peer median (excluding PHVS) | — | +27.8% | +9.7% | 87.9% | |
Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.79M | 57.38M | 65.58M | 98.56M | 124.48M |
| Selling, General & Admin | 18.35M | 29.34M | 31.34M | 47.12M | 45.34M |
| Operating Expenses | 54.14M | 86.71M | 96.91M | 145.69M | 169.82M |
| Depreciation & Amortization | 77.37K | 152.94K | 257.55K | 269.56K | 418.35K |
| EBITDA | (42.31M) | (86.56M) | (99.57M) | (145.42M) | (173.29M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (54.14M) | (86.71M) | (96.91M) | (145.69M) | (169.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 268 | 16 | 0 | 5.47M | 0 |
| Interest Expense | 278.18K | 16.11K | 0 | 0 | 0 |
| Other Income / Expenses | 11.48M | 11.06M | (2.91M) | 13.29M | (3.89M) |
| Income Before Tax | (42.66M) | (75.65M) | (99.83M) | (132.4M) | (173.71M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 70.12K | 679.09K | 1.05M | 1.83M | 1.99M |
| Net Income | (42.73M) | (76.33M) | (100.88M) | (134.22M) | (175.7M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.41) | (2.27) | (2.63) | (2.48) | (2.97) |
| EPS (Diluted) | (1.41) | (2.27) | (2.63) | (2.48) | (2.97) |
| Weighted Avg Shares | 30.41M | 33.59M | 38.39M | 54.02M | 59.16M |
| Weighted Avg Shares (Diluted) | 30.41M | 33.59M | 38.39M | 54.02M | 59.16M |
Pharvaris N.V.
NASDAQ:PHVS
Intrinsic Alpha fair value
Locked
Current Price
$31.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.